Optimization of engineered-modular endolysins expression conditions in Escherichia coli NiCo21(DE3) for the control of Streptococcal infection
Open Access
- 1 February 2020
- journal article
- research article
- Published by IOP Publishing in IOP Conference Series: Earth and Environmental Science
- Vol. 439 (1)
- https://doi.org/10.1088/1755-1315/439/1/012029
Abstract
Streptococci are Gram-positive bacteria which cause diverse animal and human diseases and systemic infections. Antibiotic therapy for this pathogen is often unsuccessful and contributes to the development of antibiotic resistance. Bacteriophage modular endolysins, as well as their chimeric constructs, represent promising antimicrobials with high specificity against these bacteria and unlikely to evoke antimicrobial resistance. Our previous work has developed the recombination and fusion engineered-modular endolysins design (namely EλC and EλCE, respectively) from a particular modular endolysin EC to obtain novel antimicrobial with enhanced activity. In this study, we investigated further the optimization of the engineered-modular endolysin expression conditions in Escherichia coli NiCo21(DE3). Accordingly, clone selection, final inducer concentration, and incubation temperature were optimized. To obtain a recombinant clone which exhibits optimum protein expression level, expressions of the recombinant protein were conducted in shake flask. Subsequently, the soluble and insoluble protein crude extracts were collected by lysis and denaturation treatments, respectively, and verified by SDS-PAGE and Western blot analysis. The result showed that the selected clone for optimum expression of EC, EλC, and EλCE was clone 1, 3, and 5, respectively. Moreover, the optimum final inducer concentration for both EλC and EC was 2000 μM, whereas for EλCE was 500 μM. Besides, the optimum incubation temperature for protein expression for EλCE was incubation at 37ºC and followed by induction at 25ºC, and for both EλC and EC were both incubation and induction at 25ºC. Furthermore, these three proteins were found to be expressed as insoluble proteins. Collectively, these results could contribute to the development of 'tailor-made' antimicrobials by modular endolysin engineering, which can be used for the control of Streptococcal infection.Keywords
This publication has 20 references indexed in Scilit:
- Bacteriophage endolysins: applications for food safetyCurrent Opinion in Biotechnology, 2016
- Invasive streptococcal disease: a review for cliniciansBritish Medical Bulletin, 2015
- Synergistic streptococcal phage λSA2 and B30 endolysins kill streptococci in cow milk and in a mouse model of mastitisApplied Microbiology and Biotechnology, 2015
- In Vitro Characterization of PlySK1249, a Novel Phage Lysin, and Assessment of Its Antibacterial Activity in a Mouse Model of Streptococcus agalactiae BacteremiaAntimicrobial Agents and Chemotherapy, 2013
- Phage and Their Lysins as Biocontrol Agents for Food Safety ApplicationsAnnual Review of Food Science and Technology, 2010
- LambdaSa1 and LambdaSa2 Prophage Lysins of Streptococcus agalactiaeApplied and Environmental Microbiology, 2007
- Bacteriophage and Peptidoglycan Degrading Enzymes with Antimicrobial ApplicationsRecent Patents on Biotechnology, 2007
- The Cell Lysis Activity of the Streptococcus agalactiae Bacteriophage B30 Endolysin Relies on the Cysteine, Histidine-Dependent Amidohydrolase/Peptidase DomainApplied and Environmental Microbiology, 2006
- Removal of Group B Streptococci Colonizing the Vagina and Oropharynx of Mice with a Bacteriophage Lytic EnzymeAntimicrobial Agents and Chemotherapy, 2005
- The bifunctional peptidoglycan lysin of Streptococcus agalactiae bacteriophage B30Microbiology, 2004